Latest news with #PeterBrady
The Age
07-07-2025
- Entertainment
- The Age
As a first-time visitor to Hawaii, one thing surprised me most
If my preconceptions of visiting Hawaii for the first time could be compared to the Hawaiian surf, they'd be the shoreline ripples at Oʻahu's child-friendly Waikiki Beach, rather than the massive breaks of Banzai Pipeline on the island's North Shore. I should know better than to underestimate a place. I blame The Brady Bunch, my childhood TV viewing where an episode featured a family visit to Waikiki. Teenager Peter Brady was plagued by a tarantula for picking up a cursed tiki. These were dreadful production blunders: tarantulas are not endemic to Hawaii, tikis represent gods and deities. I admit that I, too, got it wrong: my five-day trip blows me away. Culture is as embedded as the island's Le'ahi volcano (Diamond Head) that forms the stunning backdrop to Honolulu. Stick your head up from behind a Mai Tai cocktail at a Waikiki Beach bar, and you'll uncover – as I do – rich traditions. My arrival onto Oʻahu, the third-largest and most populated of Hawaii's eight major islands, coincides with the annual Lei Day, which celebrates the spirit and meaning of the lei, the necklace of flowers (or shells, nuts or feathers) placed over my head on arrival by my host, Noelani. 'Lei is truly about aloha in its purest form,' she says. I'm about to discover what she means. The first stop is Kapiʻolani Park, site of the 97th Oʻahu Lei Day Festival, where hundreds of locals and Native Hawaiians mingle at the craft stalls and lei-making tables that are surrounded by Indian banyan and monkeypod trees. Most attendees wear beautiful lei or lei po'o, a floral crown, that remain vibrant and fresh despite the humid breeze. Many are milling around a mature-aged gentleman, Master Lei Maker Bill Char. I'm privileged to meet this festival star, a talented ambassador of the ancient cultural practice. Suddenly, officials start scurrying (usually, locals are delightfully calm and leisurely) and cry 'The queen is coming!' I'm temporarily confused; the Hawaiian Kingdom was overthrown in 1893 and the islands were annexed by the US in 1898 as part of its expansion into the Pacific. Instead, this is royalty of another kind: it is the Lei queen, Ku'uleialoha Llanos, the year's elected 'monarch' who organises the event to keep traditions alive. This custom is far from contrived. Surprisingly, nor is our next stop: Ala Moana Centre, known as the largest open-air shopping centre in the world. Amid the chain stores, the centre's best shops are owned and run by Native and local Hawaiian designers (Native Hawaiians are indigenous, with Filipino, Japanese and other backgrounds, while local Hawaiians are generally those who live, but are not born of Hawaiian ancestry. Both will distinguish themselves as such). Malie Organics offers an array of beauty products; Noho Home is crammed with a gorgeous range of homeware items, and Big Island Candies, makes shortbreads and the likes of chocolate-dipped dried cuttlefish (the latter, a popular Hawaiian snack). I'm smitten with Manaola, where contemporary fashions feature geometric tribal motifs and Hawaiian flora. Our next stop, 'Iolani Palace, takes us into the past.
Sydney Morning Herald
07-07-2025
- Entertainment
- Sydney Morning Herald
As a first-time visitor to Hawaii, one thing surprised me most
If my preconceptions of visiting Hawaii for the first time could be compared to the Hawaiian surf, they'd be the shoreline ripples at Oʻahu's child-friendly Waikiki Beach, rather than the massive breaks of Banzai Pipeline on the island's North Shore. I should know better than to underestimate a place. I blame The Brady Bunch, my childhood TV viewing where an episode featured a family visit to Waikiki. Teenager Peter Brady was plagued by a tarantula for picking up a cursed tiki. These were dreadful production blunders: tarantulas are not endemic to Hawaii, tikis represent gods and deities. I admit that I, too, got it wrong: my five-day trip blows me away. Culture is as embedded as the island's Le'ahi volcano (Diamond Head) that forms the stunning backdrop to Honolulu. Stick your head up from behind a Mai Tai cocktail at a Waikiki Beach bar, and you'll uncover – as I do – rich traditions. My arrival onto Oʻahu, the third-largest and most populated of Hawaii's eight major islands, coincides with the annual Lei Day, which celebrates the spirit and meaning of the lei, the necklace of flowers (or shells, nuts or feathers) placed over my head on arrival by my host, Noelani. 'Lei is truly about aloha in its purest form,' she says. I'm about to discover what she means. The first stop is Kapiʻolani Park, site of the 97th Oʻahu Lei Day Festival, where hundreds of locals and Native Hawaiians mingle at the craft stalls and lei-making tables that are surrounded by Indian banyan and monkeypod trees. Most attendees wear beautiful lei or lei po'o, a floral crown, that remain vibrant and fresh despite the humid breeze. Many are milling around a mature-aged gentleman, Master Lei Maker Bill Char. I'm privileged to meet this festival star, a talented ambassador of the ancient cultural practice. Suddenly, officials start scurrying (usually, locals are delightfully calm and leisurely) and cry 'The queen is coming!' I'm temporarily confused; the Hawaiian Kingdom was overthrown in 1893 and the islands were annexed by the US in 1898 as part of its expansion into the Pacific. Instead, this is royalty of another kind: it is the Lei queen, Ku'uleialoha Llanos, the year's elected 'monarch' who organises the event to keep traditions alive. This custom is far from contrived. Surprisingly, nor is our next stop: Ala Moana Centre, known as the largest open-air shopping centre in the world. Amid the chain stores, the centre's best shops are owned and run by Native and local Hawaiian designers (Native Hawaiians are indigenous, with Filipino, Japanese and other backgrounds, while local Hawaiians are generally those who live, but are not born of Hawaiian ancestry. Both will distinguish themselves as such). Malie Organics offers an array of beauty products; Noho Home is crammed with a gorgeous range of homeware items, and Big Island Candies, makes shortbreads and the likes of chocolate-dipped dried cuttlefish (the latter, a popular Hawaiian snack). I'm smitten with Manaola, where contemporary fashions feature geometric tribal motifs and Hawaiian flora. Our next stop, 'Iolani Palace, takes us into the past.
Yahoo
19-05-2025
- Health
- Yahoo
High SCA Treatment Rates Despite Contemporary GDMT in 19,000+ Consecutive LifeVest® Patient Study
ESC Heart Failure Late Breaker: Largest single LifeVest® WCD study of NICM and MI/CAD patients shows high appropriate treatment rates during early period of contemporary GDMT CHELMSFORD, Mass., May 19, 2025--(BUSINESS WIRE)--ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced results from SCD-PROTECT, a nationwide analysis of LifeVest® wearable cardioverter defibrillator (WCD) patients in Germany, presented on May 18, 2025 as a late-breaking clinical trial at the European Society of Cardiology (ESC) Heart Failure 2025 conference. Key findings across 19,598 consecutive patients:1 Despite high overall use of contemporary GDMT, incidences of appropriate LifeVest treatments were high in both NICM and MI/CAD patients: 6.53 appropriate treatments per 100 patient-years in NICM 9.18 appropriate treatments per 100 patient-years in MI/CAD The rate of appropriate LifeVest treatments in SCD-PROTECT was higher than the ICD treatment rate reported in studies of chronic patients, indicating that results of ICD trials may not be applicable to the early period of GDMT. Median LifeVest Wear Time® per day was 23.4 and 23.5 hours in NICM and MI/CAD patients respectively. Inappropriate treatments were rare with an overall rate of 0.5% of patients. "Most notable in this study is the high rate of SCA among LifeVest patients despite wide use of GDMT, highlighting high short-term SCD risk and the need to protect these patients," said Peter Brady, MD, FRCP, FACC, FHRS, Vice President, Medical and Clinical Affairs for ZOLL Cardiac Management Solutions. "We should be thinking about LifeVest and GDMT as complementary approaches to manage SCD in the short-term." The SCD-PROTECT study adds to the body of evidence supporting LifeVest. Only LifeVest has >95% first shock success in peer-reviewed publications and real-world use,2-5 96% one-year survival data,6 and a wealth of published research covering more than 120,000 patients.2,5,7-11 "ZOLL is committed to advancing clinical research to support data-driven decision making for patients at high risk for SCD," added Brady. "Only LifeVest has been proven safe and effective in multiple peer-reviewed studies as well as real-world experience. When sudden cardiac death is on the line, patients deserve solutions backed by rigorous evidence." More than one million women and men have been protected by LifeVest, the WCD that offers robust coverage for Medicare, Medicaid, veterans and commercial patients. For more information, visit About the SCD-PROTECT Study The study titled "Sudden cardiac arrest in patients with newly diagnosed non-ischemic cardiomyopathy or myocardial infarction/coronary artery disease – Nationwide analysis of more than 19,000 patients with a wearable cardioverter-defibrillator" was presented by Johann Bauersachs and is authored by David Duncker, Eloi Marijon, Marco Metra, Olivier Piot, Marat Fudim, Uwe Siebert, Norbert Frey, Lars Siegfried Maier, and Johann Bauersachs. All patients who received a WCD from December 2021 to May 2023 in Germany were included in this epidemiological, observational, multicenter study, evaluating the SCA/SCD incidence in patients with NICM or MI/CAD during the early high-risk period before an ICD is indicated. For more information, visit About ZOLL ZOLL, an Asahi Kasei company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and cardiac monitoring, circulation enhancement and CPR feedback, supersaturated oxygen therapy, data management, ventilation, therapeutic temperature management, and sleep apnea diagnosis and treatment, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, as well as lay rescuers, improve patient outcomes in critical cardiopulmonary conditions. For more information, visit About Asahi Kasei The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber businesses, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 49,000 employees worldwide, the company contributes to a sustainable society by providing solutions to the world's challenges through its three business sectors of Material, Homes, and Health Care. Its health care operations include devices and systems for acute critical care and manufacture of biotherapeutics, as well as pharmaceuticals and diagnostic reagents. For more information, visit Asahi Kasei is also dedicated to sustainability initiatives and is contributing to reaching a carbon neutral society by 2050. To learn more, visit Duncker D, Marijon E, Metra M, Piot O, Fudim M, Siebert U, Frey N, Maier LS, Bauersachs J. Sudden cardiac arrest in patients with newly diagnosed non-ischemic cardiomyopathy or myocardial infarction/coronary artery disease – Nationwide analysis of more than 19.000 patients with a wearable cardioverter-defibrillator. Presented by Johann Bauersachs as Late-Breaking Clinical Trial at European Society of Cardiology Heart Failure 2025. May 18, 2025. Kutyifa V, Moss AJ, Klein H, et al. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: Data from the prospective registry of patients using the wearable cardioverter defibrillator (WEARIT-II Registry). Circulation 2015;132(17):1613–1619. Data on file, 90d0241_a01. Report of AArD Performance during 2019. Data on file, 90a0061_a01_revb. Clinical Evaluation Report for LifeVest Wearable Defibrillator, Model 4000, 2021. Chung MK, Szymkiewicz SJ, Shao M, et al. Aggregate national experience with the wearable cardioverter-defibrillator: Event rates, compliance, and survival. J Am Coll Cardiol. 2010;56(3):194–203. Kutyifa V, Moss A, Klein H, et al. One-Year Follow-Up of the Prospective Registry of Patients Using the Wearable Defibrillator (WEARIT-II Registry). Pacing Clin Electrophysiol. 2018;1–7. Arkles J, Delaughter C, D'Souza B. A novel artificial intelligence based algorithm to reduce wearable cardioverter-defibrillator alarms. J Interv Cardiac Electrophysiol. 2023. Garcia R, Combes N, Defaye P, et al. Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study. EP Europace. 2020;23(1):73-81. doi:10.1093/europace/euaa268. Waessnig N, Guenther M, Quick S, et al. Experience with the wearable cardioverter-defibrillator in patients at high risk for sudden cardiac death. Circulation 2016;134:635–643. Epstein AE, Abraham WT, Bianco NR, et al. Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post myocardial infarction. J Am Coll Cardiol. 2013;62(21):2000–2007. Zishiri ET, Williams S, Cronin EM, et al. Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defibrillator. Circ Arrhythm Electrophysiol. 2013;6:117–128. Copyright © 2025 ZOLL Medical Corporation. All rights reserved. ZOLL, LifeVest, and Wear Time are registered trademarks of ZOLL Medical Corporation and/or its subsidiaries in the United States and/or other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All other trademarks are the property of their respective owners. View source version on Contacts Caitlyn DoyleZOLL+1 (412) 334-4501cdoyle@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
19-05-2025
- Health
- Business Wire
High SCA Treatment Rates Despite Contemporary GDMT in 19,000+ Consecutive LifeVest® Patient Study
CHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced results from SCD-PROTECT, a nationwide analysis of LifeVest® wearable cardioverter defibrillator (WCD) patients in Germany, presented on May 18, 2025 as a late-breaking clinical trial at the European Society of Cardiology (ESC) Heart Failure 2025 conference. Key findings across 19,598 consecutive patients: 1 Despite high overall use of contemporary GDMT, incidences of appropriate LifeVest treatments were high in both NICM and MI/CAD patients: 6.53 appropriate treatments per 100 patient-years in NICM 9.18 appropriate treatments per 100 patient-years in MI/CAD The rate of appropriate LifeVest treatments in SCD-PROTECT was higher than the ICD treatment rate reported in studies of chronic patients, indicating that results of ICD trials may not be applicable to the early period of GDMT. Median LifeVest Wear Time® per day was 23.4 and 23.5 hours in NICM and MI/CAD patients respectively. Inappropriate treatments were rare with an overall rate of 0.5% of patients. 'Most notable in this study is the high rate of SCA among LifeVest patients despite wide use of GDMT, highlighting high short-term SCD risk and the need to protect these patients,' said Peter Brady, MD, FRCP, FACC, FHRS, Vice President, Medical and Clinical Affairs for ZOLL Cardiac Management Solutions. 'We should be thinking about LifeVest and GDMT as complementary approaches to manage SCD in the short-term.' The SCD-PROTECT study adds to the body of evidence supporting LifeVest. Only LifeVest has >95% first shock success in peer-reviewed publications and real-world use, 2-5 96% one-year survival data, 6 and a wealth of published research covering more than 120,000 patients. 2,5,7-11 'ZOLL is committed to advancing clinical research to support data-driven decision making for patients at high risk for SCD,' added Brady. 'Only LifeVest has been proven safe and effective in multiple peer-reviewed studies as well as real-world experience. When sudden cardiac death is on the line, patients deserve solutions backed by rigorous evidence.' More than one million women and men have been protected by LifeVest, the WCD that offers robust coverage for Medicare, Medicaid, veterans and commercial patients. For more information, visit About the SCD-PROTECT Study The study titled "Sudden cardiac arrest in patients with newly diagnosed non-ischemic cardiomyopathy or myocardial infarction/coronary artery disease – Nationwide analysis of more than 19,000 patients with a wearable cardioverter-defibrillator" was presented by Johann Bauersachs and is authored by David Duncker, Eloi Marijon, Marco Metra, Olivier Piot, Marat Fudim, Uwe Siebert, Norbert Frey, Lars Siegfried Maier, and Johann Bauersachs. All patients who received a WCD from December 2021 to May 2023 in Germany were included in this epidemiological, observational, multicenter study, evaluating the SCA/SCD incidence in patients with NICM or MI/CAD during the early high-risk period before an ICD is indicated. For more information, visit About ZOLL ZOLL, an Asahi Kasei company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and cardiac monitoring, circulation enhancement and CPR feedback, supersaturated oxygen therapy, data management, ventilation, therapeutic temperature management, and sleep apnea diagnosis and treatment, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, as well as lay rescuers, improve patient outcomes in critical cardiopulmonary conditions. For more information, visit About Asahi Kasei The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber businesses, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 49,000 employees worldwide, the company contributes to a sustainable society by providing solutions to the world's challenges through its three business sectors of Material, Homes, and Health Care. Its health care operations include devices and systems for acute critical care and manufacture of biotherapeutics, as well as pharmaceuticals and diagnostic reagents. For more information, visit Asahi Kasei is also dedicated to sustainability initiatives and is contributing to reaching a carbon neutral society by 2050. To learn more, visit Duncker D, Marijon E, Metra M, Piot O, Fudim M, Siebert U, Frey N, Maier LS, Bauersachs J. Sudden cardiac arrest in patients with newly diagnosed non-ischemic cardiomyopathy or myocardial infarction/coronary artery disease – Nationwide analysis of more than 19.000 patients with a wearable cardioverter-defibrillator. Presented by Johann Bauersachs as Late-Breaking Clinical Trial at European Society of Cardiology Heart Failure 2025. May 18, 2025. Kutyifa V, Moss AJ, Klein H, et al. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: Data from the prospective registry of patients using the wearable cardioverter defibrillator (WEARIT-II Registry). Circulation 2015;132(17):1613–1619. Data on file, 90d0241_a01. Report of AArD Performance during 2019. Data on file, 90a0061_a01_revb. Clinical Evaluation Report for LifeVest Wearable Defibrillator, Model 4000, 2021. Chung MK, Szymkiewicz SJ, Shao M, et al. Aggregate national experience with the wearable cardioverter-defibrillator: Event rates, compliance, and survival. J Am Coll Cardiol. 2010;56(3):194–203. Kutyifa V, Moss A, Klein H, et al. One-Year Follow-Up of the Prospective Registry of Patients Using the Wearable Defibrillator (WEARIT-II Registry). Pacing Clin Electrophysiol. 2018;1–7. Arkles J, Delaughter C, D'Souza B. A novel artificial intelligence based algorithm to reduce wearable cardioverter-defibrillator alarms. J Interv Cardiac Electrophysiol. 2023. Garcia R, Combes N, Defaye P, et al. Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study. EP Europace. 2020;23(1):73-81. doi:10.1093/europace/euaa268. Waessnig N, Guenther M, Quick S, et al. Experience with the wearable cardioverter-defibrillator in patients at high risk for sudden cardiac death. Circulation 2016;134:635–643. Epstein AE, Abraham WT, Bianco NR, et al. Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post myocardial infarction. J Am Coll Cardiol. 2013;62(21):2000–2007. Zishiri ET, Williams S, Cronin EM, et al. Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defibrillator. Circ Arrhythm Electrophysiol. 2013;6:117–128. Copyright © 2025 ZOLL Medical Corporation. All rights reserved. ZOLL, LifeVest, and Wear Time are registered trademarks of ZOLL Medical Corporation and/or its subsidiaries in the United States and/or other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All other trademarks are the property of their respective owners.
